Antibodies and chimeric antigen receptors specific for ROR1

US11919970B2 · kind B2 · utility

Assignee

• Juno Therapeutics, Inc. · US

Inventors

• Yan Chen · Santa Clara, US
• Steven M. Shamah · Acton, US
• Csaba Pazmany · Belmont, US
• Jui Dutta-Simmons · Framingham, US

Key dates

• Filing date: Dec 14, 2020
• Grant date: Mar 5, 2024
• Expiry date: Feb 22, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are ROR1 binding molecules, including anti-ROR1 antibodies, including antibody fragments such as variable heavy chain (VH) regions, single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). In some embodiments, the antibodies specifically bind to ROR1. Among the antibodies are human antibodies, including those that compete for binding to ROR1 with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.